Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kerem Ozer

Endocrinology, Diabetes & Metabolism Round Rock, TX Medical Doctor

NPI 1982878617 CMS profile 363120

170 Deepwood Dr, Suite 104, Round Rock, TX 78681

Open in the dashboard

General payments

$219,992

501 records reported · program years 2019–2023

Research payments

$19,099

Paid to them · 9 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,046,137 paid to institutions, not to them · program years 2019–2021

Through program year 2023, Kerem Ozer of Round Rock, TX is reported in the CMS Open Payments database as having received $219,992 across 501 general payments and $19,099 in research payments paid to them. Separately, studies naming them as principal investigator received $2,046,137 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $187 1
2023 Research $174 1
2022 Research $285 1
2021 General $20,570 30
2021 Research $641 3
2020 General $61,304 120
2020 Research $13,979 3
2019 General $137,931 350
2019 Research $4,020 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerem Ozer
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Kerem Ozer were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Kerem Ozer Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $137,931 $494 $123–$2,253 $163
2020 $61,304 $335 $85–$1,841 $114
2021 $20,570 $398 $88–$1,981 $132
2022 $0 $364 $88–$1,568 $149
2023 $187 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lilly USA, LLC $139,275 355 payments
  2. Novo Nordisk Inc $38,345 58 payments
  3. AstraZeneca Pharmaceuticals LP $14,620 21 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $11,987 23 payments
  5. Janssen Pharmaceuticals, Inc $4,568 7 payments
  6. Sanofi-Aventis U.S. LLC $3,621 2 payments
  7. IBSA Pharma Inc. $2,614 9 payments
  8. Dexcom, Inc. $2,426 2 payments
  9. Clarus Therapeutics Inc. $2,150 2 payments
  10. Medtronic MiniMed, Inc. $53 2 payments
  11. Other $334 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $177,571 141 payments
  2. Consulting Fee $16,704 9 payments
  3. Travel and Lodging $15,678 146 payments
  4. Food and Beverage $6,278 200 payments
  5. Honoraria $3,750 3 payments
  6. Education $11 2 payments
Products named General payments · program years 2019–2023
  1. TRULICITY $70,126 171 payments
  2. BAQSIMI $26,096 73 payments
  3. JARDIANCE Diabetes $15,313 47 payments
  4. Ozempic $15,196 25 payments
  5. FARXIGA $14,620 21 payments
  6. JARDIANCE Diabetes $11,987 23 payments
  7. Tresiba $10,693 17 payments
  8. INVOKANA $4,568 7 payments
  9. SOLIQUA 100/33 $3,621 2 payments
  10. Tirosint $2,614 9 payments
  11. Other $16,801 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Eli Lilly and Company $19,099 9 payments

Records

510 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record